BIO-key International first-quarter total revenue up 81%

NewsGuard 100/100 Score

BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in finger-based biometric identification solutions, today reported financial results for the first quarter ended March 31, 2010. For clarity and consistency, the data presented in this release includes only the results of the Company's fingerprint-based Biometrics Division for such period.  The Company completed the sale of its Law Enforcement Division on December 8, 2009.

2010 First Quarter Consolidated Results

Total revenue for the three months ended March 31, 2010 was $976,175 representing an increase of 81% from the $538,194 reported for the quarter ended March 31, 2009. 

BIO-key's gross margin for the first quarter of 2010 was 89.0% compared to 75% for the same period in 2009.  Operating expenses for the first quarter of 2010 were reduced by 13% to $984,809 compared to expenses of $1,128,729 in the quarter ended March 31, 2009.  First quarter 2010 operating loss was $118,734, significantly improved from an operating loss of $727,614 in the first quarter of 2009. Accounting for income from derivative and warrant fair value adjustments and income from discontinued operations, BIO-key's net income for the first quarter of 2010 was $1,000,558 compared to net income of $222,049 for the first quarter of 2009

"We are very pleased with our first quarter financial results," said Michael DePasquale, BIO-key's Chief Executive Officer. "Top line revenue growth increased 81% from the same period in 2009 gross margin improved by 14 percentage points and expenses declined 13%.  Our Biometrics business is doing well and we are positioned to continue executing our plan for solid growth and profitability in 2010."

DePasquale went on to say, "Our sales and margins continued to improve on a year-over-year basis, and sequentially.  With stable and high margins and a relatively fixed overhead structure, the key for our company will be top-line growth.  With the many projects underway, our goal is to post sequential improvements in sales, and over time, generate higher returns for our shareholders."

Liquidity and Capital Resources

Consolidated cash, cash equivalents and accounts receivables totaled over $1.8 million on March 31, 2010. The total included $482,523 in cash due BIO-key from a contract delivered under our arrangement with Interact Public Safety Systems and recorded as discontinued operations.

Highlights for the first quarter included the following:

  • Contract award in excess of  $530,000 from the Oklahoma Blood Institute, the 11th largest non-profit regional blood center in America for the deployment of our WEB-key software for donor identification
  • Purchase orders totaling over $490,000 from McKesson for their continued deployment of our identification technology in their AccuDose® product line
  • Purchase orders for continued expansion of biometric ID deployments with commercial partners ChoicePoint /Nexis Lexis, AT&T, Educational Biometric Technology, Identimetrics and NextGenID
  • An order from partner Evidian for the deployment of our technology at another major Pharmaceutical Company as part of their Enterprise Single Sign–On Solution
  • A  purchase order for additional software licenses from ACT, the not-for-profit organization that provides a broad array of assessment, research, information, and program management solutions
  • NIST test results of our most recent algorithm submission report an improvement of 23% in overall accuracy. In the DHS2 dataset, the most challenging of the four datasets used in this testing, BIO-key ranked as one of the top three providers worldwide.  
  • Launch of TruDonor ID™, the first SaaS (Software as a Service) biometric ID solution. This fully hosted identity solution is tailored to address the needs of the blood collection industry.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Non-invasive blood test shows 83% sensitivity in detecting colorectal cancer, offering hope for early diagnosis